296 results on '"Siemeister, Gerhard"'
Search Results
2. DNA repair inhibitors sensitize cells differently to high and low LET radiation
3. An Antagonistic Vascular Endothelial Growth Factor (VEGF) Variant Inhibits VEGF-Stimulated Receptor Autophosphorylation and Proliferation of Human Endothelial Cells
4. Suppl. Figure 1 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
5. Supplementary Table 1 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
6. Supplementary Figures from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
7. Supplementary Methods from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
8. Suppl. Figure 2 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
9. Suppl. Figure 4 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
10. Supplementary Materials and Methods; Supplementary Tables 1-6; and Supplementary Figure Legends from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
11. Supplementary Table 4 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
12. Data from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
13. Supplementary Table 6 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
14. Supplementary Figure 2 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
15. Supplementary Tables from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
16. Suppl. Figure 3 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
17. Supplementary Figure 1 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
18. Supplementary Table 3 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
19. Supplementary Table 2 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
20. Data from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
21. Supplementary Table 5 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
22. Radiobiological effects of the alpha emitter Ra-223 on tumor cells
23. Supplementary Table S1 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
24. Supplementary Table 2 from Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation
25. Figure S2 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
26. Supplementary Table 1 from Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation
27. Supplementary Table 3 from Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation
28. Supplemental Figure 5 from Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation
29. Supplementary Figure Legends and Methods from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
30. Supplementary Figure 4 from Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation
31. Supplementary Figure 2 from Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation
32. Supplementary Table 4 from Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation
33. Supplementary Figure 3 from Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation
34. Supplementary Figure 1 from Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation
35. Supplementary Methods, Legends for Videos and Figures from Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
36. Data from Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
37. Supplementary Video 3 from Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
38. Supplementary Figure 6 from Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
39. Supplementary Figure 1 from Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
40. Supplementary Figure 4 from Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
41. Supplementary Video 5 from Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
42. Supplementary Video 2 from Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
43. Supplementary Table 4 from Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
44. Supplementary Table 2 from Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
45. Supplementary Video 4 from Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
46. Supplementary Table 1 from Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
47. Supplementary Figure 5 from Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
48. Supplementary Video 1 from Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
49. Supplementary Table 3 from Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
50. Supplementary Figure 2 from Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.